A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
← catalyst calendarNCT06293053 · readout in 435 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-15 | actual | When the study began enrolling |
| Primary completion | 2027-10-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-03 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prurigo Nodularis
Intervention
- Drug: Dupilumab — also filed as SAR231893, Dupixent
Primary outcome
what the primary-completion date above is the date OFConcentration of dupilumab in serum
measured Day 1 to Week 40
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed